JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient